

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Donna M. Bryant, RN, MSN, ANP-BC, OCN, CCRC	POSITION TITLE Executive Director Clinical Research Mary Bird Perkins – Our Lady of the Lake Cancer Center
eRA COMMONS USER NAME 12091288	

EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Louisiana Tech University	BS	1981	Education
Alcorn State University	A.D.	1983	Nursing
Loyola University	BSN	1994	Nursing
University of South Alabama	MSN	1997	Nursing

A. Personal Statement

With more than 25 years of clinical training and research experience, I began my successful career with an Associate’s Degree in Science in Nursing (1983). Practicing as a registered nurse for 15 years, running the gamut from intensive care to nursing administration, while earning a Bachelor’s of Science in Nursing from Loyola University (1994), and a Master’s of Science in Nursing while completing the Adult Acute Care Nurse Practitioner program at the University of South Alabama (1997), my experiences are vast.

Upon graduation as a Nurse Practitioner, I joined a private medical oncology practice, becoming the first Oncology Nurse Practitioner in Baton Rouge, LA., and started a Clinical Trials Office. I obtained national certification as an Oncology Certified Nurse® by the Oncology Nursing Society (1998). With experience as a study coordinator and clinical research administrator, I have extensive experience in clinical trial management; trial coordination; project management and coordination; budget development; training of clinical research personnel; and orientation and site development and management.

Having managed more than 200 oncology related clinical trials spanning all phases of clinical research, I achieved national certification as a Certified Clinical Research Coordinator from the Association of Clinical Research Professionals (2005). I have co-authored and published many peer-reviewed abstracts and posters, and journal articles related to clinical research activities, and are a frequent speaker at the local, state, and national levels. Having the opportunity to work with leading cancer experts through the NCI’s NCCCP program has been a highlight of my career in Oncology.

I have been with Mary Bird Perkins Cancer Center (MBPCC) since 2005, serving as the Director of Clinical Research for MBPCC and for all of Mary Bird Perkins hospital partners, namely Mary Bird Perkins – Our Lady of the Lake Cancer Center, Mary Bird Perkins Cancer Center at St. Tammany Parish Hospital, and Mary Bird Perkins Cancer Center at Terrebonne General Medical Center. Since 2005, I have worked closely in collaboration with the LSUHSC MB-CCOP in New Orleans, LA. I am responsible for the oversight, management and strategic research business development of all clinical research activities and operations for multiple research sites in MBPCC’s 18 parish service region. Actively involved on the local level in the National Cancer Institute Community Cancer Centers Program (NCCCP) since 2007, I have served as Co-Chair for the NCCCP Screening and Accrual Log Workgroup that created both the inaugural version – developed from August 2007 through the log launch in January 2008 – and the second iteration developed and implemented in March 2009. I have participated as a site leader for all NCCCP activities through serving on many of the NCCCP Sub-Committees since 2007.

I have also championed the NCCCP Quality of Care initiatives by leading the efforts of the ASCO Quality Oncology Practice Initiatives for our participating medical oncology practices. Through these efforts, I have been responsible for assisting Louisiana Hematology Oncology Associates to obtain QOPI certification in 2010, and am currently leading the process for QOPI recertification this year.

I am an active member in many professional organizations including the American Society of Clinical Oncology, Association of Cancer Executives, Oncology Nursing Society, and American Academy of Nurse

Practitioners, the Association of Clinical Research Professionals and the Society of Clinical Research Associates. My responsibility for the proposed Gulf-South MB-NCORP will be to function as the Lead CRA for the Mary Bird Perkins component and sub-component sites.

B. Positions and Honors

Positions

1983-1985 - LaSalle General Hospital, Staff RN and Charge Nurse, Medical/Surgical Unit and Emergency Room, Jena, Louisiana
1985-1998 - Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana
1998-2005 - Medical Oncology, LLC, Adult Nurse Practitioner, Clinical Research Coordinator/Dept. Manager, Baton Rouge, Louisiana
2005-2006 - Louisiana Hematology Oncology Associates, Adult Nurse Practitioner, Clinical Research Coordinator, Baton Rouge, Louisiana
2008-2010 - National Cancer Institute, Cancer Biomedical Information Grid - caBIG®
2006-Present - Southeast Louisiana Radiation Oncology Group, Nurse Practitioner, Baton Rouge, LA
2006-Present - Mary Bird Perkins – Our Lady of the Lake Cancer Center
2009-Present - Mary Bird Perkins Cancer Center at St. Elizabeth Hospital, Executive Director of Clinical Research, Gonzales, Louisiana
2009-Present - Mary Bird Perkins Cancer Center at Terrebonne General Medical Center, Executive Director of Clinical Research, Houma, Louisiana
2011-Present - Mary Bird Perkins Cancer Center at St. Tammany Parish Hospital, Executive Director, Covington, Louisiana

Honors:

1983 Loyola University Nursing Honor Society
1994 Alpha Sigma Lambda Honor Society
1995 Baton Rouge District Nurses Association Nursing Excellence Award
1996 Sigma Theta Tau National Nursing Honor Society Loyola University Chapter
2002 Louisiana State Nurses Association Nightingale Award Finalist

C. Selected peer-reviewed publications (in chronological order).

1. Servodidio, C.A., **Bryant, D.**, Duggan, B., Ellison, C., Gonzalez, M., Neri, D., and Sprouse, N. Nursing Leadership of Successful Clinical Trial Recruitment Strategies to an NCCCP Endorsed Study. Podium and Poster presented at Oncology Nursing Society Congress, San Antonio, TX, April 30, 2009
2. Grubbs, S.S., Gonzalez, M., Krazna, M., Siegel, R., **Bryant, D.**, Tschetter, L., Hayenga, L., Duggan, B., St. Germaine, D., Denicoff, A. Tracking Clinical Trial Accrual Strategies and Barriers via a Web-Based Screening Tool: Abstract #6856) American Society of Clinical Oncology Annual Meeting, 2009.
3. **Bryant, D.M.** Panel Presentation: Clinical Oncology Nursing/Practitioner Roundtable Panel Presentation. Perspectives in Oncology: New Orleans, Louisiana, November 2009.
4. St. Germaine, D., Denicoff, A.M., Gonzalez, M.M., Duggan, B., Einolf, S., Grubbs, S., **Bryant, D.M.**, Sprouse, N., Kaul, R., Sherbeck, M., Hood, D., Brown, T., Kniola, D., Lord, C., and McCaskill-Stevens, W. Development of a Web-Based Clinical Trial Screening and Accrual Log to Enhance Accrual via the NCI Community Cancer Centers Program (NCCCP). ASCO Poster Presentation, 2010.
5. Gonzales, M.M., St. Germain, D., Denicoff, A.M., Berger, M., Hood, D., Wilkinson, S., Osen, S., Jones, W., Fournier, J., Ellison, C., Kniola, D., Kaul, R., **Bryant, D.**, and McCaskill-Stevens, W. Engaging Patient Navigators to Enhance Participation of Underserved Populations to Clinical Trials Accrual in the NCI Community Cancer Centers Program (NCCCP). ASCO Poster Presentation, 2010.

6. Neuss, M., Hertler, A., Hendricks, C., King, K., **Bryant, D.** ASCO QOPI® Luncheon Panel Presentation: Certification Program Participants, ASCO 2010 Annual Meeting, Chicago, Illinois, June 2010.
7. Kadlubek, P., Gilmore, T., **Bryant, D.**, and Castro, K. ASCO QOPI® Certification Webinar for NCCCP sites. February 2011
8. Gonzales, M., Berger, M., **Bryant, D.**, Ellison, C., Harness, J., Krasna, M., Oelmann, R., Wilkinson, K. Using a Minority Matrix and Patient Navigation to Improve Accrual to Clinical Trials. *Oncology Issues*, 2011; 26(2): 59-60
9. Gonzales, M., Berger, M., Brown, T., **Bryant, D.**, Hugg, J.; Kaul, R., Krasna, M., Lord, C., Lowen, S., Smith, S., Sprouse, N. Using an Online Tool to Understand and Improve Clinical Trial Accruals. *Oncology Issues*, 2011: 26 (2): 50-55.
10. Zaren HA, Nair S, Go RS, Enos RA, Lanier KS, Thompson MA, Zhao J, Fleming DL, Leighton JC, Gribbin TE, **Bryant DM**, Carrigan A, Corpening JC, Csapo KA, Dimond EP, Ellison C, Gonzalez MM, Harr JL, Wilkinson K, Denicoff AM. Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment. *J Oncol Pract*. 2013 Mar;9(2):e55-61. PMC3595451.

D. Research Support

Current Research Support

- U10CA063845 (NIH NCI) Veith (PI) 06/01/2009 – 05/31/2014
LSUHSC Minority-Based Community Clinical Oncology Program
The goal of this project is to increase minority participation in state-of-the-art, NCI clinical trials in the Greater New Orleans area and surrounding regions.
Role: Director of Clinical Research for MBPCC
- MBPCC-PS-1204 (Celldex) Olson (PI) 05/16/2012 -
Vaccine therapy among newly diagnosed glioblastoma patients.
The primary objective of the study is to confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.
- KLT_PANC-001 Bienvenu (PI) 06/03/2013 -
Advanced pancreatic cancer.
The goal of this study is to compare the effect of gemcitabine + Kanglaite Injection (KLTi) to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer, not amenable to curative surgical resection.
- PH3-01 (Present) Spell (PI) 12/20/2011 -
Vaccine therapy in early stage HER2 low breast cancer.
The primary objective is to compare the disease-free survival (DFS) in subjects with operable early-stage, node-positive breast cancer who receive standard of care multimodality therapy plus NeuVax with rhGM-CSF as the treatment group or standard of care multimodality therapy plus the placebo with the vaccine adjuvant, rhGM-CSF (sargramostim) as the control group.
- TALC McWhorter (PI) 7/28/2011 -
Laryngeal cancer observational study.
The immediate goals of this study are to compare the impact of primary chemoradiation versus surgery on patients with new tumors of the hypopharynx and cartilage-invading larynx) that would require total laryngectomy for cure.

MCC14690 (Total Cancer Care) Vincent (PI)

10/01/2008 -

Created a clinical data and tissue repository.

The overall objective of this study is to develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and “personalized medicine.”

TCGA (Total Cancer Genome Atlas Project)

Vincent (PI)

09/2013 -

Biospecimen procurement program.

The TCGA project is designed to try to identify all of the genetic changes that can cause cancer in people by studying the genetic and biochemical material from various types of cancer tissue collected.

Connect CLL

Bienvenu (PI)

4/27/2010 -

Chronic Lymphocytic Leukemia Disease Registry

Describe practice patterns of first-line therapy regimens and subsequent therapeutic strategies in patient initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting.

Completed Research Support

Phase I – Phase IV clinical trials.

Multiple NCI sponsored Cooperative group clinical trials including RTOG, CALGB, NSABP, ECOG, SWOG, NCCTG, and CCCWFU.

Multiple academic and institutional sponsored clinical trials.

Multiple pharmaceutical sponsored clinical trials.